Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Preferred Stock Liabilities (2020 - 2021)

Cytek Biosciences (CTKB) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $194.3 million as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $194.3 million, compared with a TTM value of $194.3 million through Jun 2021, changed N/A, and an annual FY2020 reading of $194.3 million, changed N/A over the prior year.
  • Preferred Stock Liabilities was $194.3 million for Q2 2021 at Cytek Biosciences, roughly flat from $194.3 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $194.3 million in Q4 2020 and bottomed at $194.3 million in Q4 2020.